CASI Pharmaceuticals Inc (CASI.O) :
<ul>
<li>CASI PHARMACEUTICALS ANNOUNCES PLAN TO SUBMIT IND APPLICATION FOR CID-103, AN ANTI-CD 38 ANTIBODY IN ANTIBODY-MEDIATED REJECTION, AND RECEIPT OF A NON-BINDING PROPOSAL TO ACQUIRE ENTIRE CHINA BUSINESS OF THE COMPANY</li>
<li>CASI PHARMACEUTICALS INC - TO SUBMIT IND APPLICATION FOR CID-103 BY END OF 2024</li>
<li>CASI PHARMACEUTICALS INC - BOARD GOT A PRELIMINARY NON-BINDING PROPOSAL LETTER DATED JUNE 21, FROM WEI-WU HE, CHAIRMAN OF BOARD AND CEO OF COMPANY</li>
<li>CASI PHARMACEUTICALS INC - PROPOSED DEAL FOR PURCHASE PRICE OF $40.0 MILLION, WHICH SHALL INCLUDE ASSUMPTION OF UP TO $20.0 MILLION OF INDEBTEDNESS OF COMPANY</li>
</ul>

CASI

CASI Pharmaceuticals plans to submit an IND application for CID-103, an anti-CD 38 antibody, by the end of 2024. They have also received a non-binding proposal to acquire their entire China business for a purchase price of $40 million.

Reuters

CASI Pharmaceuticals

Casi Pharmaceuticals Announces Plan To Submit Ind Application For Cid-103, An Anti-Cd 38 Antibody In Antibody-Mediated Rejection, And Receipt Of A Non-Binding Proposal To Acquire Entire China Business Of The Company